$REVB

REVELATION BIOSCIENCES, INC.

Revelation Biosciences is a clinical-stage life science company based in San Diego, California. It develops Gemini, a proprietary formulation of PHAD®, to modulate inflammatory responses. Its programs evaluate Gemini for acute kidney injury, as a short-term treatment, and chronic kidney disease, as a long-term treatment. The company also studies Gemini’s potential use in other conditions and seeks to expand its pipeline with technologies addressing kidney-related issues. Revelation’s work centers on preclinical research and clinical development of therapeutic candidates. Its current programs include GEM-AKI and GEM-CKD; the company has obtained FDA agreement on a Phase 2/3 study design for GEM-AKI and has conducted clinical studies of Gemini in healthy volunteers and patients with chronic kidney disease. It relies on third parties to manufacture candidates for preclinical and clinical testing and has an exclusive worldwide license from Vanderbilt University to develop and commercialize PHAD for treating or preventing infections.

1
0
0

No SEC Form 4 filings for $REVB in the last 30 days.

See all $REVB insider activity →
Med

Revelation Biosciences announces development plan, partnership initiatives

Revelation Biosciences (REVB) announced plans to accelerate development of its therapeutic candidate Gemini, including a Phase 2a clinical study for acute kidney injury, with data expected in late 2027. The company is also pursuing partnerships and licensing opportunities to support Gemini's development and commercialization.

Revelation Biosciences Reports $3.3 Million Third-Quarter Net Loss

Revelation Biosciences reported a net loss of $3.3M for Q3 2026, with operating expenses rising to $3.4M from $1.9M in Q3 2025. The company has $9.1M in cash, expected to fund operations into Q2 2027. It is developing Gemini for kidney diseases and infections, with a potential $94B market according to an independent assessment.

REVB sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning REVB (REVELATION BIOSCIENCES, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent REVB coverage spans earnings, technology and corporate actions.

What's driving REVB

AlphAI scores every news story that mentions REVB with an AI model for sentiment and relevance, and aggregates insider trades from REVELATION BIOSCIENCES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $REVB

Score

Revelation Biosciences 3Q 2026: EPS ($5.92) — 10-Q Summary

Revelation Biosciences reported a wider net loss for 3Q 2026, with expenses rising due to increased R&D and administrative costs. The company has no revenue. GEM-AKI program and manufacturing costs drove much of the expense growth. Cash reserves were $9.1M, but not enough for a full year of operations. Diluted EPS was ($5.92).

$REVBLowEarnings

Revelation Biosciences, Inc. Announces Financial Results

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 SAN DIEGO – November 5, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developi

$REVBMedAI 8/10

Revelation Aiming for Paradigm Shift in Kidney Disease Care

Revelation Biosciences (REVB) is developing Gemini, a drug candidate for acute and chronic kidney disease, post-surgical infections, and severe burns. The company plans to launch a Phase 2/3 study for acute kidney injury later this year, with completion expected in about two years. CEO James Rolke highlights Gemini's potential to reduce inflammation and prevent scar tissue, citing positive pre-clinical and early clinical results. Revelation aims to submit Gemini for FDA approval if the study mee

REVELATION BIOSCIENCES, INC. (REVB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

REVELATION BIOSCIENCES, INC. (REVB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 17, 2026, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Revelation Biosc

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

Revelation Biosciences (NASDAQ:REVB) reported financial results for the three and six months ended June 30, 2026. Cash and cash equivalents rose to $11.5M from $10.7M at Dec. 31, 2025, and it expects funding through Q1 2027. Net loss was $3.3M ($0.87/share) for Q2 and $6.3M ($3.41/share) for six months. The company also advanced Gemini AKI Phase 2/3 start-up and formed an AKI advisory board.

Related tickers